PCSK9 INHIBITION-MEDIATED REDUCTION IN TRIGLYCERIDE WITH EVOLOCUMAB IS RELATED TO BASELINE TRIGLYCERIDE LEVELS: AN ANALYSIS FROM 1791 PATIENTS

Two decades ago all statins demonstrated effective triglyceride (TG) reductions although mainly in hypertriglyceridemic (HTG) patients. The studies supported increased receptor (LDLR) mediated removal of TG-rich lipoproteins (LP) in subjects with increased concentrations of these LPs; however